Receive in-depth updates on the latest in GI and hepatology, endoscopy, and practice management when you attend one or more of the optional Friday courses. Four courses are offered: two half-day courses, the GI Pathophysiology Course and the What’s New in GI Pharmacology Course; and two full-day courses, the Practice Management Summit and the ASGE Endoscopy Course.Register for any two courses and save up to 10%!
Can’t join us in-person in Las Vegas?
Maximize your learning with one of our VIRTUAL All-Access Pass options and save 20%!
ACG All-Access Pass: The ACG All-Access Pass includes virtual-only access to the GI Pathophysiology Course, GI Pharmacology Course, Practice Management Summit, Postgraduate Course + Bonus Sessions (formerly Learning Luncheons), and the Annual Scientific Meeting + Bonus Sessions (formerly Breakfast Sessions). Registrants will also receive online access to the 2021 Self-Assessment Test.
NEW for 2021: ACG All-Access Pass + ASGE Endoscopy Course: The ACG All-Access Pass includes virtual-only access to all of the courses in the ACG All-Access Pass PLUS the ASGE Endoscopy Course.
GI Pathophysiology Course
Friday, October 22, 2021 | 7:00 am - 12:30 pm | Mandalay Bay Ballroom F
Course Directors: Darwin L. Conwell, MD, MS, FACG, and Ikuo Hirano, MD, FACG
Gain a better understanding of gastrointestinal disease processes and their impact on clinical presentation of patients when you attend the GI Pathophysiology Course. Experts will review the underlying causes and clinical implications of commonly encountered diseases seen in practice.
|Friday, October 22, 2021 │ All times are listed in the Pacific Time Zone|
|7:00 am||Welcome and Introductions
Darwin L. Conwell, MD, MS, FACG and Ikuo Hirano, MD, FACG
|7:05 am||Gastrointestinal and Hepatic Implications of COVID-19
Luis F. Lara, MD
Identify the clinical implications of gastrointestinal and hepatic manifestations of SARS-CoV-2.
|7:35 am||Proton Pump Inhibitor Adverse Effects: Fact or Fiction?
Paul Moayyedi, MB ChB, PhD, MPH, FACG
Describe the scientific rationale and evidence for adverse effects of proton pump inhibitor therapy.
|8:05 am||Scientific Foundations of Novel Immunologic Approaches to IBD
Miguel D. Regueiro, MD, FACG
Apply concepts regarding the immunologic basis of novel biologic therapies to the management of IBD.
|8:35 am||Rationale for Targeting Eosinophils in Achalasia, Eosinophilic Gastrointestinal Disease,
and Functional Gastrointestinal Disorders
Nirmala P. Gonsalves, MD
Appreciate the rationale for growing interest in novel therapies targeting eosinophils in the management of achalasia, eosinophilic gastrointestinal disease, and functional GI disorders.
|9:05 am||Q & A|
|9:55 am||Pathophysiology Basis for Current and Future Management of Acute Pancreatitis
George I. Papachristou, MD, PhD, FACG
Identify the scientific basis for novel therapeutic approaches to pancreatitis.
|10:25 am||Application of Molecular and Genetic Testing to the Management of Colon Polyps and Cancer
Elena M. Stoffel, MD, MPH
Formulate a clinical approach to the use of molecular and genetic testing in the evaluation and management of colon polyps and cancer.
|10:55 am||Mechanistic Underpinnings for the Management of Refractory Constipation
Darren M. Brenner, MD, FACG
Apply concepts regarding the physiologic basis of constipation to inform therapeutic decisions for patients with refractory constipation.
|11:25 am||Celiac Disease: From Disease Understanding to Management Strategies
Amy S. Oxentenko, MD, FACG
Detail the mechanisms of celiac disease as well as diagnostic and management strategies for patients.
|11:55 am||Q & A and Course Wrap-Up|
|12:30 pm||Course Adjourns|